Online inquiry

IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10220MR)

This product GTTS-WQ10220MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets RHD gene. The antibody can be applied in prevention of feto-maternal allo-immunization in RhD- women research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001127691.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6007
UniProt ID Q02161
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10220MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13830MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-10987
GTTS-WQ1441MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ4603MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ392MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 20D7S
GTTS-WQ14628MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ5609MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ10295MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ2613MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 557
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW